[Drug therapy for the treatment of portal hypertension].
Imai
F
F
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D003131:Combined Modality Therapy; D004232:Diuretics / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006975:Hypertension, Portal / Q000188:drug therapy* / Q000503:physiopathology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D005996:Nitroglycerin / Q000627:therapeutic use; D017082:Portal Pressure / Q000187:drug effects; D011412:Propanolamines / Q000627:therapeutic use; D015911:Sclerotherapy; D013004:Somatostatin / Q000627:therapeutic use; D013148:Spironolactone / Q000627:therapeutic use; D014662:Vasoconstrictor Agents / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use; D014667:Vasopressins / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D004232:Diuretics; D011412:Propanolamines; D014662:Vasoconstrictor Agents; D014665:Vasodilator Agents; D014667:Vasopressins; D013148:Spironolactone; D013004:Somatostatin; C036089:nipradilol; D005996:Nitroglycerin